Glassman Sees 'Fine Line' for Off-Label Drug Marketing
- 00:05:34
- Bloomberg
Glassman 'Suspicious' of Government-Mandated Health Care
Ferguson Discusses U.S. Banking System, Economy: Video
Faber Says Stocks May Develop Rally 'Relatively Soon'
Richard Weiss Says Equity Market is 'Fairly Attractive'
Amato Sees Increasing Investor Willingness to Buy Stocks
Hainer `Cautiously Optimistic' on Adidas's Sales Outlook: Video
Previous Page
Next Page
Glassman Sees 'Fine Line' for Off-Label Drug Marketing
Robert Glassman, private equity partner at OrbiMed Advisors, talks with Bloomberg's Erik Schatzker and Deirdre Bolton about the practice of so-called off-label drug marketing and its impact on the industry.
Bloomberg | November 9, 2009
